Notoginsenoside Ft1 acts as a TGR5 agonist but FXR antagonist to alleviate high fat diet-induced obesity and insulin resistance in mice.

Lili Ding; Qiaoling Yang; Eryun Zhang; Yangmeng Wang; Siming Sun; Yingbo Yang; Tong Tian; Zhengcai JU; Linshan Jiang; Xunjiang Wang; Zhengtao Wang; Wendong Huang; Li Yang

Return

Notoginsenoside Ft1 acts as a TGR5 agonist but FXR antagonist to alleviate high fat diet-induced obesity and insulin resistance in mice.

Author: Lili DING ¹ ; Qiaoling YANG ¹ ; Eryun ZHANG ¹ ; Yangmeng WANG ² ; Siming SUN ² ; Yingbo YANG ¹ ; Tong TIAN ¹ ; Zhengcai JU ¹ ; Linshan JIANG ¹ ; Xunjiang WANG ¹ ; Zhengtao WANG ¹ ; Wendong HUANG ² ; Li YANG ¹
Author Information

1. Shanghai Key Laboratory of Complex Prescriptions and MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
2. Department of Diabetes Complications and Metabolism, Diabetes and Metabolism Research Institute, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA 91010, USA.
Publication Type:Journal Article
Keywords: ANOVA, analysis of variance; AUC, area under the curve; BAT, brown adipose tissue; BAs, bile acids; Bile acids; DIO, diet-induced obesity; FGF, fibroblast growth factor; FXR; Ft1, notoginsenoside Ft1; Fxr, nuclear farnesoid X receptor; GLP-1; GLP-1, glucagon-like peptide-1; GTT, glucose tolerance test; HFD, high fat diet; ITT, insulin tolerance test; Insulin resistance; KO, knockout; Metabolic disorders; Notoginsenoside Ft1; Obesity; TGR5; Tgr5, membrane-bound G protein-coupled receptor; Ucp, uncoupling protein; Wt, wild-type; cAMP, adenosine 3′,5′ cyclic monophosphate; eWAT, epididymal white adipose tissue; iWAT, inguinal white adipose tissue
From: Acta Pharmaceutica Sinica B 2021;11(6):1541-1554
CountryChina
Language:English
Abstract: Obesity and its associated complications are highly related to a current public health crisis around the world. A growing body of evidence has indicated that G-protein coupled bile acid (BA) receptor TGR5 (also known as Gpbar-1) is a potential drug target to treat obesity and associated metabolic disorders. We have identified notoginsenoside Ft1 (Ft1) from